What does PAQ Therapeutics do?
PAQ Therapeutics is a clinical-stage biotechnology company based in Burlington, MA that focuses on developing KRAS degraders for lethal cancers that currently lack effective treatment options.
How much did they raise?
The company raised $39M in a Series B round led by Bayland Capital and MRL Ventures Fund, with additional participation from Johnson & Johnson Innovation – JJDC, Inc., LAV Fund, BioTrack Capital, and existing investor Sherpa Health Partners.
What are their plans for the money?
The funds will support the next stage of clinical development for PAQ Therapeutics' lead asset, PT0253, which could pave the way for transformative cancer treatments.
What have they achieved so far?
Previously, PAQ Therapeutics successfully completed a $30M Series A financing in 2021, underscoring early investor confidence in its approach to combating KRAS-driven cancers.
